Research Analysts Issue Forecasts for AMLX FY2029 Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Investment analysts at HC Wainwright raised their FY2029 earnings per share estimates for shares of Amylyx Pharmaceuticals in a research note issued on Tuesday, February 10th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.80 per share for the year, up from their prior estimate of $0.21. HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2030 earnings at $2.29 EPS.

Several other research firms have also weighed in on AMLX. Lifesci Capital upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 27th. Citigroup raised their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Amylyx Pharmaceuticals Stock Up 0.4%

AMLX opened at $14.12 on Thursday. Amylyx Pharmaceuticals has a 52-week low of $2.60 and a 52-week high of $17.49. The company has a 50 day moving average of $13.39 and a two-hundred day moving average of $12.55. The company has a market cap of $1.55 billion, a P/E ratio of -7.84 and a beta of -0.31.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC raised its holdings in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after acquiring an additional 2,487,617 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Amylyx Pharmaceuticals by 7.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after purchasing an additional 143,065 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $1,541,000. Los Angeles Capital Management LLC bought a new position in shares of Amylyx Pharmaceuticals during the second quarter worth about $149,000. Finally, Acadian Asset Management LLC lifted its position in shares of Amylyx Pharmaceuticals by 135.1% during the second quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock worth $3,645,000 after purchasing an additional 326,976 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, CEO Joshua B. Cohen sold 1,974 shares of Amylyx Pharmaceuticals stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.83, for a total transaction of $27,300.42. Following the sale, the chief executive officer directly owned 3,379,465 shares of the company’s stock, valued at approximately $46,738,000.95. The trade was a 0.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Justin B. Klee sold 1,995 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $13.89, for a total value of $27,710.55. Following the sale, the chief executive officer owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. This trade represents a 0.06% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 157,783 shares of company stock valued at $2,122,808. Company insiders own 12.30% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.